/
/
/

Glaxosmithkline Pharmaceuticals Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018
₹938 Cr₹995 Cr₹1041 Cr₹980 Cr₹805 Cr₹974 Cr₹949 Cr₹1011 Cr₹815 Cr₹930 Cr₹805 Cr₹957 Cr₹762 Cr₹787 Cr₹802 Cr₹917 Cr₹745 Cr₹810 Cr₹816 Cr₹1010 Cr₹718 Cr₹744 Cr₹792 Cr₹879 Cr₹649 Cr₹776 Cr₹779 Cr₹882 Cr₹788 Cr₹751 Cr₹825 Cr₹816 Cr₹736 Cr
₹44 Cr₹36 Cr₹32 Cr₹34 Cr₹44 Cr₹41 Cr₹35 Cr₹35 Cr₹36 Cr₹30 Cr₹28 Cr₹28 Cr₹36 Cr₹28 Cr₹23 Cr₹22 Cr₹28 Cr₹19 Cr₹10 Cr₹15 Cr₹32 Cr₹30 Cr₹14 Cr₹9 Cr₹58 Cr₹16 Cr₹17 Cr₹16 Cr₹31 Cr₹53 Cr₹17 Cr₹15 Cr₹18 Cr
₹982 Cr₹1031 Cr₹1073 Cr₹1014 Cr₹849 Cr₹1015 Cr₹984 Cr₹1045 Cr₹850 Cr₹960 Cr₹833 Cr₹985 Cr₹798 Cr₹815 Cr₹826 Cr₹939 Cr₹773 Cr₹828 Cr₹826 Cr₹1025 Cr₹750 Cr₹774 Cr₹806 Cr₹888 Cr₹707 Cr₹792 Cr₹795 Cr₹898 Cr₹819 Cr₹804 Cr₹842 Cr₹831 Cr₹754 Cr
₹659 Cr₹658 Cr₹690 Cr₹662 Cr₹569 Cr₹656 Cr₹676 Cr₹706 Cr₹601 Cr₹691 Cr₹604 Cr₹686 Cr₹634 Cr₹635 Cr₹590 Cr₹676 Cr₹612 Cr₹650 Cr₹636 Cr₹751 Cr₹603 Cr₹605 Cr₹629 Cr₹696 Cr₹556 Cr₹625 Cr₹673 Cr₹711 Cr₹642 Cr₹602 Cr₹700 Cr₹663 Cr₹611 Cr
₹339 Cr₹387 Cr₹403 Cr₹369 Cr₹295 Cr₹374 Cr₹327 Cr₹356 Cr₹266 Cr₹287 Cr₹246 Cr₹318 Cr₹180 Cr₹197 Cr₹252 Cr₹279 Cr₹177 Cr₹194 Cr₹208 Cr₹291 Cr₹164 Cr₹186 Cr₹195 Cr₹214 Cr₹172 Cr₹189 Cr₹141 Cr₹210 Cr₹196 Cr₹216 Cr₹154 Cr₹180 Cr₹154 Cr
₹97 L₹61 L₹1 Cr₹51 L₹42 L₹58 L₹9 L₹27 L₹37 L₹77 L₹32 L₹43 L₹28 L₹65 L₹9 L₹39 L₹68 L₹28 L₹58 L₹35 L₹79 L₹63 L₹94 L₹88 L₹1 Cr₹2 Cr₹3 Cr₹92 L₹93 L₹8 L₹5 L₹22 L₹20 L
₹322 Cr₹373 Cr₹400 Cr₹354 Cr₹279 Cr₹359 Cr₹308 Cr₹344 Cr₹249 Cr₹271 Cr₹65 Cr₹299 Cr₹181 Cr₹190 Cr₹224 Cr₹262 Cr₹160 Cr₹208 Cr₹172 Cr₹274 Cr₹146 Cr₹49 Cr₹187 Cr₹127 Cr₹149 Cr₹177 Cr-₹634 Cr₹587 Cr₹176 Cr₹222 Cr₹170 Cr₹157 Cr₹134 Cr
₹237 Cr₹278 Cr₹296 Cr₹257 Cr₹205 Cr₹263 Cr₹230 Cr₹253 Cr₹182 Cr₹194 Cr₹46 Cr₹218 Cr₹132 Cr₹133 Cr₹165 Cr₹193 Cr₹119 Cr₹1219 Cr₹150 Cr₹204 Cr₹121 Cr₹14 Cr₹157 Cr₹76 Cr₹111 Cr₹138 Cr-₹661 Cr₹503 Cr₹114 Cr₹147 Cr₹114 Cr₹101 Cr₹84 Cr

Share Price Live Stats

Open (₹)2,938.90
Volume (₹)21,902.00
High (₹)2,972.80
Upper Circuit3,525.00
Low (₹)2,934.40
Lower Circuit2,350.00
Prev Close2,937.50
52W High (₹)3,120.70
Price2,945.20
52W Low (₹)2,088.10

Share Market Cap & Key Ratios Overview

M.Cap (₹)49726.60 Cr
Div. Yield (%)1.94
PE Ratio46.55
Debt to Equity0.00
Price to Book16.94
Book Value134.77
EPS (TTM)63.05
Face Value10.00
ROE (%)48.76

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
GLAXONSE
LTP
1W Low
1W High
Market cap (₹)
1901.2-18.8 (-0.98%)
1900.10
1984.80
4,56,833Cr
9185.5-53.5 (-0.58%)
9087
9467
2,45,426Cr
4858-192 (-3.80%)
4854
5066
1,87,320Cr
1131.6-59.4 (-4.99%)
1125.10
1187
1,13,217Cr
1380.4-43.1 (-3.03%)
1376.70
1426.10
1,12,212Cr
1852.1-86.4 (-4.46%)
1811.70
1949
1,01,155Cr
2122-49.5 (-2.28%)
2118.10
2192
97,626Cr
2336-46.9 (-1.97%)
2335
2419.20
96,859Cr
1162.2-15.8 (-1.34%)
1154.40
1179.90
96,406Cr
1659.2+13.9 (0.84%)
1622.60
1717
93,614Cr
2945.2-161.2 (-5.19%)
2908.50
3120
49,727Cr

Key Highlights of Glaxosmithkline Pharmaceuticals Ltd’s P&L

In 2026-03-31, Glaxosmithkline Pharmaceuticals Ltd reported total revenue of ₹3967.03Cr, compared with ₹3895.14Cr in 2025-03-31, reflecting Glaxosmithkline Pharmaceuticals Ltd turnover.

Depreciation was ₹66.44Cr and finance costs were ₹2.73Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹1406.01Cr in 2026-03-31 as compared to ₹1259.88Cr in 2025-03-31.

Net Profit (PAT) was ₹1035.98Cr in 2026-03-31 compared with ₹927.58Cr in 2025-03-31.

Earnings per share (EPS) were ₹61.15 in 2026-03-31, compared with ₹54.76 in 2025-03-31.